Clinical Trials Logo
  1. Home
  2. Lung Cancer
  3. NCT04215913
  4. Details
NCT04215913 Clinical Trial

Integrative Analysis of Pulmonary Sarcomatoid Carcinoma (PSC)

Lung Cancer Clinical Trial

— PSC  

Official title:
Integrative Analysis of Pulmonary Sarcomatoid Carcinoma (PSC)

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT04215913
Other study ID # 2019-FD52Rainy-PSC
Secondary ID FD52Rainy
Status Not yet recruiting
Phase
First received
Last updated
Start date December 30, 2019
Est. completion date December 24, 2025

Study information
Verified date December 2019
Source Shanghai 10th People's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Integrative Analysis of pulmonary sarcomatoid carcinoma (PSC)

Description:

The investigators will analyzed proteomes of paired normal lung tissues and pulmonary sarcomatoid carcinoma with or without metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary pulmonary sarcomatoid carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 300
Est. completion date December 24, 2025
Est. primary completion date December 24, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Age = 70 years with histologically proven LCLC

- No severe major organ dysfunction

- World Health Organization (WHO) performance status of 0 or 1

- No prior cancer chemotherapy

Exclusion Criteria:

- Age = 70

- Severe major organ dysfunction

- WHO performance status of >1

- Prior cancer chemotherapy

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• The investigators will extract total protein, DNA and RNA from PSC patients.
The investigators will extract total protein, DNA and RNA from PSC patients.

Locations
Country Name City State
China Da Fu Shanghai Shanghai

Sponsors (3)
Lead Sponsor Collaborator
Shanghai 10th People's Hospital Anhui Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China

Country where clinical trial is conducted

China, 

References & Publications (1)

Boland JM, Mansfield AS, Roden AC. Pulmonary sarcomatoid carcinoma-a new hope. Ann Oncol. 2017 Jul 1;28(7):1417-1418. doi: 10.1093/annonc/mdx276. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary 10 years overall survival 10 years overall survival 10 years overall survival
Secondary 10 years disease-free survival 10 years disease-free survival 10 years disease-free survival
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk